Product Description
Mechanisms of Action: TGFR Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00115427 |
NCT00115427 | P1 |
Completed |
Parkinson's Disease |
None |
2019-03-21 |
Treatments |
|
NCT00111982 |
Protocol 20020168 | P2 |
Completed |
Parkinson's Disease |
2005-11-01 |
2019-03-21 |
Treatments |